Kainos Medicine, Inc. (KOSDAQ: 284620)
South Korea
· Delayed Price · Currency is KRW 3,975.00
-25.00 (-0.63%)
Nov 15, 2024, 9:00 AM KST
Kainos Medicine Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2019 | FY 2018 | FY 2017 | FY 2014 | FY 2013 | 2012 - 2009 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '20 Mar 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | 2012 - 2009 |
| Revenue | - | - | - | - | 145.28 | 100 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | - | 45.28% | 1100.05% | Upgrade
|
| Cost of Revenue | - | - | - | - | 25.07 | 1.61 | Upgrade
|
| Gross Profit | - | - | - | - | 120.22 | 98.39 | Upgrade
|
| Selling, General & Admin | - | - | - | - | 967.48 | 1,271 | Upgrade
|
| Research & Development | - | - | - | - | 1,257 | 1,151 | Upgrade
|
| Other Operating Expenses | -60.74 | -44.18 | -25.92 | -42.27 | 6.41 | 3.46 | Upgrade
|
| Operating Expenses | -60.74 | -44.18 | -25.92 | -42.27 | 2,238 | 2,516 | Upgrade
|
| Operating Income | 60.74 | 44.18 | 25.92 | 42.27 | -2,117 | -2,417 | Upgrade
|
| Interest & Investment Income | - | - | - | - | 27.71 | 35.79 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | -3.79 | 27.26 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | 4.41 | -0.68 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | -29.41 | 5.34 | -25.38 | Upgrade
|
| EBT Excluding Unusual Items | 60.74 | 44.18 | 25.92 | 12.86 | -2,084 | -2,380 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 15.3 | -54.39 | Upgrade
|
| Asset Writedown | - | - | - | - | - | -6,719 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | 3,354 | Upgrade
|
| Pretax Income | 60.74 | 44.18 | 25.92 | 12.86 | -2,068 | -5,800 | Upgrade
|
| Income Tax Expense | 20.82 | 20.82 | 21.97 | -25.07 | - | - | Upgrade
|
| Net Income | 39.92 | 23.36 | 3.95 | 37.93 | -2,068 | -5,800 | Upgrade
|
| Net Income to Common | 39.92 | 23.36 | 3.95 | 37.93 | -2,068 | -5,800 | Upgrade
|
| Net Income Growth | 174.64% | 491.64% | -89.59% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 6 | 5 | 0 | - | 9 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 6 | 5 | 0 | - | 9 | 8 | Upgrade
|
| Shares Change (YoY) | 1474.97% | 1405.00% | - | - | 15.34% | 9.20% | Upgrade
|
| EPS (Basic) | 6.18 | 4.32 | 11.00 | - | -235.00 | -760.00 | Upgrade
|
| EPS (Diluted) | 6.18 | 4.32 | 11.00 | - | -235.00 | -760.00 | Upgrade
|
| EPS Growth | -82.56% | -60.69% | - | - | - | - | Upgrade
|
| Free Cash Flow | 169.79 | 185.74 | -22.01 | -27.23 | -2,072 | -3,281 | Upgrade
|
| Free Cash Flow Per Share | 26.28 | 34.39 | -61.33 | - | -235.44 | -429.90 | Upgrade
|
| Gross Margin | - | - | - | - | 82.75% | 98.39% | Upgrade
|
| Operating Margin | - | - | - | - | -1457.48% | -2417.34% | Upgrade
|
| Profit Margin | - | - | - | - | -1423.77% | -5799.98% | Upgrade
|
| Free Cash Flow Margin | - | - | - | - | -1426.41% | -3280.83% | Upgrade
|
| EBITDA | - | - | - | - | -2,076 | -2,307 | Upgrade
|
| D&A For EBITDA | - | - | - | - | 41.8 | 110.09 | Upgrade
|
| EBIT | 60.74 | 44.18 | 25.92 | 42.27 | -2,117 | -2,417 | Upgrade
|
| Effective Tax Rate | 34.28% | 47.13% | 84.77% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.